Skip to main content

Cannabis: Medical Treatments

Question for Home Office

UIN 48249, tabled on 18 May 2020

To ask the Secretary of State for the Home Department, with reference to paragraphs 4 and 5 on page 3 of her Department's Factsheet on Cannabis, CBD and other cannabinoids, what assessment she has made of the limit of detection that is the appropriate level of sensitivity to accurately determine through laboratory analysis that there are no controlled cannabinoids present in a CBD product and that the product contains CBD in its pure form.

Answered on

2 June 2020

The Department has made no assessment of limits of detection in relation to testing for the presence of controlled cannabinoids in CBD products. The Home Office approach is one of caution, that is, that a CBD product is likely to be controlled under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001 (‘the 2001 Regulations’) if it contains any controlled cannabinoids.

The term ‘administration’ in the exempt product definition is not defined by the 2001 Regulations. The Human Medicines Regulations 2012 provides the following as part of its definition:

““administer” means administer to a human being—

(a) orally, by injection, or by introduction into the body in any other way; or

(b) by external application (whether or not by direct application to the body)”

The interpretation of legislation is ultimately a matter for the courts to decide.

Answered by

Home Office
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.
Interests declared
The Member has declared that they have interests which may be relevant to the subject matter of this question.